Breathe Well Live Well
Conditions: Asthma; Moderate Asthma
Interventions: Drug: REGN3500; Drug: Placebo
Sponsors: Regeneron Pharmaceuticals; Sanofi
Not yet recruiting – verified December 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Conditions: Healthy Volunteers; Asthma
Interventions: Drug: RP3128; Drug: Placebo
Sponsor: Rhizen Pharmaceuticals SA
Recruiting – verified November 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Bronchial Asthma
Interventions: Drug: Intravenous magnesium sulfate; Drug: Inhaled budesonide; Drug: normal saline
Sponsor: Hamad Medical Corporation
Recruiting – verified May 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: PBF-680; Drug: Placebo
Sponsors: Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau; Palo Biofarma, S.L
Recruiting – verified August 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
menifee247 |
Elite Clinical Trials Test Doses of Dulera for Asthma
menifee247 The primary coordinator of the asthma study, clinical research coordinator Stefanie Richardson, says most of patients participating in the study either don't have medical insurance or they simply cannot afford to pay the co-pay for the asthma therapy. |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: Placebo to BI 1060469; Drug: BI 1060469 Healthy; Drug: Placebo to BI 1060469 asthmatics; Drug: BI 1060469 asthmatics
Sponsor: Boehringer Ingelheim
Not yet recruiting – verified April 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Elite Clinical Trials Tests Varying Dulera Doses for Asthma
menifee247 “When the study is over, these patients are able to go to their doctor and inform them that they had fewer asthma symptoms with Dulera and have their PCP prescribe this medication for them [now] versus waiting several years for a medication to be … |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: Indacaterol 27.5 mcg; Drug: Indacaterol 37.5; Drug: Indacaterol 55 mcg; Drug: Indacaterol 75 mcg; Drug: Indacaterol 150 mcg; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting – verified October 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Identifying asthma patients who tolerate lower doses of steroids remains …
Medical Xpress Common respiratory measurements are not effective in determining which asthma patients are able to significantly decrease their use of inhaled corticosteroid (ICS) medications without risk of flare-ups or exacerbations, according to a new study … Predicting Response to Therapy in Mild Persistent Asthma |
View full post on asthma – Google News
|
Identifying asthma patients who tolerate lower doses of steroids remains …
Science Codex ATS 2012, SAN FRANCISCO – Common respiratory measurements are not effective in determining which asthma patients are able to significantly decrease their use of inhaled corticosteroid (ICS) medications without risk of flare-ups or exacerbations, … Predicting Response to Therapy in Mild Persistent Asthma |
View full post on asthma – Google News